Patent classifications
A61K31/164
Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing
Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:
A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,
where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH.sub.2—CO—, and L1 and L2 independently are —[CH.sub.2].sub.p1— and —[CH.sub.2].sub.p2—, where p1 and p2, independently, are 0 or integers ranging from 1-10.
METHOD OF TREATING NEUROPATHIC PAIN WITH A SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING PALMITOYLETHANOLAMIDE AND L-ACETYLCARNITINE
A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanoiamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.
METHOD OF TREATING NEUROPATHIC PAIN WITH A SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING PALMITOYLETHANOLAMIDE AND L-ACETYLCARNITINE
A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanoiamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.
METHOD OF TREATING NEUROPATHIC PAIN WITH A SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING PALMITOYLETHANOLAMIDE AND L-ACETYLCARNITINE
A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanoiamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.
COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL
The present disclosure provides a composition comprising Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof. The composition may further comprise one or more other active agents. In an embodiment, the composition is formulated as an oral formulation. The compositions of the present disclosure may find utility in treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral, pharyngeal, oropharyngeal and esophageal diseases or conditions using the advantageous compositions of the present disclosure.
COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL
The present disclosure provides a composition comprising Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof. The composition may further comprise one or more other active agents. In an embodiment, the composition is formulated as an oral formulation. The compositions of the present disclosure may find utility in treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral, pharyngeal, oropharyngeal and esophageal diseases or conditions using the advantageous compositions of the present disclosure.
Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep
Provided are compositions comprising cannabinol; one or more agents selected from a flavanol, an endocannabinoid, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, and homodihydrocapsaicin; and, optionally, melatonin, and methods of making such compositions. The disclosed compositions can be useful in, for example, treating a sleep disorder (e.g., insomnia, seasonal affective disorder, or jet lag). The disclosed compositions can also be useful in inducing and/or promoting sleep. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep
Provided are compositions comprising cannabinol; one or more agents selected from a flavanol, an endocannabinoid, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, and homodihydrocapsaicin; and, optionally, melatonin, and methods of making such compositions. The disclosed compositions can be useful in, for example, treating a sleep disorder (e.g., insomnia, seasonal affective disorder, or jet lag). The disclosed compositions can also be useful in inducing and/or promoting sleep. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
ORONASAL CBD FORMULATIONS AND USES THEREOF
Provided herein are oronasal formulations including a cannabinoid and N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM). Also provided are methods of using the formulations.
ORONASAL CBD FORMULATIONS AND USES THEREOF
Provided herein are oronasal formulations including a cannabinoid and N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM). Also provided are methods of using the formulations.